Drug Profile
Buprenorphine depot - Camurus
Alternative Names: Brixadi (buprenorphine) extended-release injection for subcutaneous use; Brixadi Monthly; Brixadi Weekly; Brixadi™; Buvidal; CAM 2038; CAM 2048Latest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator Camurus
- Developer Braeburn Pharmaceuticals; Camurus
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Opioid-related disorders
- Phase III Pain
- Phase I/II Postoperative pain
Most Recent Events
- 05 Sep 2023 Launched for Opioid-related disorders in USA (SC, Controlled release, once montly)
- 05 Sep 2023 Launched for Opioid-related disorders in USA (SC, Controlled release, once weekly)
- 29 May 2023 Braeburn Pharmaceuticals anticipates launch of buprenorphine depot for Opioid-related disorders in USA in September 2023